sarcopenia and glp 1 Glucagon‐like peptide‐1 receptor agonists muscle strength changes in older adults: Risks beyond muscle mass reductions - Prokopidis - British Journal of Pharmacology Balancing weight and muscle loss

Fine lines and a loss of firmness creeping in

Here's a snapshot of what CVS Caremark will and won't cover under its updated formulary: Why It Matters Zepbound and Wegovy are not interchangeable

Results announced in December 2025 confirmed the Phase 2 findings at a longer timepoint (Lilly Press Release, Dec 2025): The 28.7% weight loss at 68 weeks exceeds both semaglutide (~15% in STEP trials) and tirzepatide (~22.5% in SURMOUNT trials) at similar timepoints

Some metabolic pathways link NAD availability to antioxidant defense systems

Gatica D, Lahiri V, Klionsky DJ

This is your last story for now Register to get unlimited access to all of FDLs curated content